Helen Yang

General Manager of Sinovac Biotech
Ms. Guang Yang (Helen) served as the general manager of Sinovac Biotech (Hong Kong) Ltd. as well as the head of investor relations and secretary to the Board of Directors of Sinovac Biotech Ltd. Ms. Yang is a key member of the company executive team, responsible for global business strategy formulation and execution. MS. Yang joined Sinovac since the year of 2003 and has had approximately 20 years experiences in vaccine industry. She has an excellent leadership, building the company’s global business platform and led the team to expand the business to cover more than 50 countries in the past 10 years.
Ms. Yang obtained her MBA with outstanding graduate results from Peking University & Vlerick Leuven Gent Management School, Belgium in 2011; She received a Master of Science (Hons) in ISMA International Securities Investment and Banking from the University of Reading, UK in 2003. Bachelor of Economics (Hons) from China Agricultural University and University of Colorado Denver International School in 2002.

Presentation Summary 
Summary Presentation of Helen Yang from SINOVAC
The sudden epidemic of Covid-19 is a challenge facing all mankind, and it poses unprecedented challenges to vaccine development  in countries around the world... At the opening ceremony of the 73rd World Health Assembly, China solemnly promised to make vaccines a global public product. The global epidemic is raging, and Sinovac is implementing the concept ofa community of human health and wellness with practical deeds.
According to the national and international epidemic situation, Sinovac takes overall considerations of domestic and foreign needs, and reasonably allocates vaccine supplies. in research, production, and use of Covid-19 vaccine, we all have active lnternational cooperation (global supply, establishment ofa factory in Egypt, BRIC countries, ete.). Sinovac actively promotes other related study on Covid-19 vaccine, including Real-World Study, lmmune Persistence Study, ete., to provide references for further large-scale use of the vaccine (Real-World Study in Chile, Brazil and lndonesia, Age-Extension Study, Variant Strain Study, ete.).
Virus is our common enemy, and the whole world is a community with a shared future for mankind. The epidemic is far from terminate. lf one place is not safe, everyone won' t be safe. "it will be fine that everyone is fine!" We must Fight Covid-19 together in this protracted battle.